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Non-osteoporotic skeletal-related events (SREs) are clinically important markers of disease 
progression in prostate cancer. We developed and validated an approach to identify SREs in 
men with prostate cancer using routinely-collected data. 
Methods: 
Patients diagnosed with prostate cancer between January 2010 and December 2013 were 
identified in the National Prostate Cancer Audit, based on English cancer registry data. A 
coding framework was developed based on diagnostic and procedure codes in linked 
national administrative hospital and routinely-collected radiotherapy data to identify SREs 
occurring before December 2015. Two coding definitions of SREs were assessed based on 
whether the SRE codes were paired with a bone metastasis code (‘specific definition’) or 
used in isolation (‘sensitive definition’). We explored the validity of both definitions by 
comparing the cumulative incidence of SREs from time of diagnosis according to prostate 
cancer stage at diagnosis with death as a competing risk. 
Results: 
We identified 40,063, 25,234 and 13,968 patients diagnosed with localised, locally advanced 
and metastatic disease, respectively. Using the specific definition, we found that the 5-year 
cumulative incidence of SREs was 0.8% in patients with localised disease, 6.0% in patients 
with locally advanced disease, and 42.2% in patients with metastatic disease. Using the 







The comparison of the cumulative incidence of SREs identified in routinely collected hospital 
data, based on a specific coding definition in patients diagnosed with different prostate 
cancer stage, supports their validity as a clinically important marker of cancer progression. 
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Prognostic or therapeutic determinants of the outcomes of prostate cancer patients often 
need a long follow-up period due to the natural history of this disease, which may be 
protracted. In order to report on patient survival a long follow-up is required. Markers of 
disease progression – or disease recurrence after initial successful treatment – could 
therefore be attractive alternative outcomes because they occur earlier in the course of the 
disease (1). 
 
National or regional cancer registries are highly effective at identifying patients who have 
been diagnosed with cancer but they often fail to recognise patients whose cancer has 
progressed or recurred. This is also true of many cancer trials, where long-term follow up is 
often restricted, resulting in a failure to detect events that occur late in the course of the 
disease. Administrative hospital data in the United States and Denmark have been used to 
identify one of the key progression markers in prostate cancer, non-osteoporotic skeletal-
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related events (SREs) (2-7).  These encompass pathological fractures, spinal cord 
compression, radiotherapy for bone metastases, or bone surgery. This highlights the 
possibility of using this measured event as a marker of disease progression or recurrence, 
allowing for an observation of the true natural history of prostate cancer, and as a clinically 
important event in its own right. 
 
We developed a coding framework in data available in the National Prostate Cancer Audit to 
identify non-osteoporotic SREs in routinely collected hospital data, consisting of three 
national datasets linked at patient level. We validated this framework firstly by assessing 
how often identified SREs were ‘paired’ with a diagnosis code for bone metastasis, secondly 
by estimating the 5-year cumulative incidence of SREs according to prostate cancer stage at 
the time of diagnosis, and thirdly by comparing the incidence of SREs observed with our 
coding framework against results of other studies. 
 
 
2. MATERIAL AND METHODS: 
2.1 Patient population 
We identified 152,851 men diagnosed with prostate cancer between January 1, 2010 and 
December 31, 2013 in the National Prostate Cancer Audit (8), according to the International 
Classification of Diseases, 10th Edition (ICD-10) code for prostate cancer (C61) (9) available in 
English cancer registry data. Men were categorised according to their cancer stage at the 
time of diagnosis (localised, locally advanced, or metastatic prostate cancer), according to a 
method developed by the National Prostate Cancer Audit (10). This categorisation is based 
on criteria recommended by the UK National Institute for Health and Care Excellence (11). It 
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uses Gleason score and TNM stage items that are available in the English cancer registry. 
Patients with M1 were categorised as having metastatic disease and in the remaining 
patients anyone with N1, T stage ≥3, Gleason score ≥8 or PSA >20 were categorised as 
having locally advanced disease. The cancer registry also provided the date of diagnosis. 
 
The cancer registry dataset was linked to the Hospital Episode Statistics (HES) database (12), 
an administrative database of all hospital episodes in the English NHS (also including 
mortality data from the Office for National Statistics) and to the National Radiotherapy 
Dataset (RTDS) (13), a database of all radiotherapy treatment episodes in England. Follow-
up was available up to December 31, 2015. Diagnosis codes in HES are based on ICD-10 
codes and procedure codes according to the fourth revision of the Office of Population, 
Censuses and Surveys Classification of Surgical Operations and Procedures (OPCS-4) (14). 
Men with missing data for cancer stage at the time of diagnosis (n = 63,586) were excluded 
(Figure 1). 
 
2.2 Coding philosophy 
Men who develop metastatic disease cannot reliably be identified as such in the English 
cancer registry or HES database because they are not always admitted to hospital and if 
admitted, the presence of metastatic disease is not always recorded. For that reason, we 
aimed to identify the first occurrence of a SRE, given that it is a serious complication of 
metastatic prostate cancer that typically results in a hospital-related treatment episode. The 
cumulative incidence of SREs underestimates the overall rate of disease progression, but it 
is likely to be a reliable and robust reflection of a clinically important, serious and costly 
complication of metastatic disease. 
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Our coding framework detects non-osteoporotic SREs in three ways. First, we identified 
diagnosis codes in HES for ‘pathological fractures’ or ‘spinal cord compression’. Second, we 
identified procedure codes in HES for ‘bone surgery’. Third, we identified codes in the linked 
RTDS to identify palliative radiotherapy. 
 
2.3 Diagnosis codes 
Based on earlier studies, a comprehensive a priori list of diagnosis codes related to SREs was 
generated. This list was informed by previous publications (15) and expert input from the 
co-authors who had a range of clinical backgrounds (MGP, AS, PC, HP, NC, AA). This step is 
termed ‘forward coding’. Codes for osteoporosis with pathological fractures (M800-9) were 
not included within this forward coding step in order to include only pathological fractures 
caused by bone metastases and not those solely caused by osteoporosis (given that men 
with prostate cancer are at risk of both). This is particularly relevant in light of the recent 
findings of the ERA-223 trial which set out to investigate the combination effect of adding 
radium-223 to abiraterone acetate and prednisolone/prednisolone in patients with 
castration-resistant metastatic prostate cancer. Radium-223 was shown to be contributing 
to an increased risk of osteoporotic fractures and led to the exclusion of osteoporotic events 
in this study (16).  
 
The records of the hospital episodes in the HES database, identified through forward coding, 
were explored for additional common diagnosis codes that are likely to be related to a SRE. 
Diagnosis codes found through this step of ‘backward coding’ were added to the code list. 
Backward coding was used because it is likely to add codes that are able to capture the 
idiosyncrasies of real-world coding practice that are difficult to identify otherwise. Expert 
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input from the co-authors was again used to ensure that inclusion of these additional codes 
was appropriate. 
 
2.4 Procedure codes 
In an earlier study (14) forward coding, was used to identify procedure codes related to 
surgery for bone metastases in the HES data set. Backward coding was also used to search 
for additional procedure codes. 
 
2.5 Radiotherapy codes 
Linkage to the RTDS was used to identify patients who had undergone radiotherapy for 
prostate cancer. Men were considered to have undergone radiotherapy to metastatic sites if 
in linked RTDS records the treatment region was coded as ‘metastasis’, if the treatment 
intent was coded as ‘non-curative’ and treatment region was missing, or if a radiotherapy 
episode occurred after a hospital episode in the HES database that included a diagnosis 
code for bone metastasis (‘secondary malignant neoplasm of bone and marrow’ [C795]). We 
only used a single code for bone metastasis (C795) for this purpose because other possible 
diagnosis codes for bone metastases (‘malignant neoplasm of vertebral column’ (C412) or 
‘malignant neoplasm of pelvic bones, sacrum and coccyx’ (C414)) were never observed. 
 
2.6 Validation 
We validated the coding framework in three steps. First, we looked at how often diagnosis 
and procedure codes related to a SRE were ‘paired’ with the diagnosis code for bone 
metastasis (C795) in the same hospital episode in the HES database. In the cases where the 
SRE was identified in the RTDS, pairing was defined as the occurrence of a diagnosis code for 
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bone metastasis in a hospital episode which was within 6 months of the palliative 
radiotherapy start date as recorded in the RTDS. This step reflects that we can distinguish 
two coding definitions: a ‘specific definition’ in which the SRE codes are paired with a code 
for bone metastasis, and a ‘sensitive definition’ in which SRE codes are used in isolation. 
 
Second, we investigated the association of the cumulative incidence of SREs after prostate 
cancer diagnosis with cancer stage at the time of diagnosis. Third, we compared the 
incidence of SREs, observed with our coding framework, with the results of other studies. 
 
2.7 Statistical analysis 
The 5-year cumulative incidence of SREs was estimated, with death being treated as a 
competing event (17). Men were followed up from the date of their prostate cancer 
diagnosis until their first SRE or until December 31, 2015, whichever came first. The data 




3.1 Coding framework to identify SREs in administrative hospital data and routinely-
collected radiotherapy data 
We included 79,265 men of whom 40,063 had localised disease, 25,234 had locally 
advanced disease, and 13,968 had metastatic disease at the time of diagnosis. The cohort 
was followed up and SREs were identified based on the coding framework generated 
through forward coding. Using the records of patients identified as having a SRE in this way, 
we identified two further diagnosis codes through backward coding: ‘fracture of bone in 
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neoplastic disease’ (M907) and ‘myelopathy in disease classified elsewhere’ (G992). The 
final list for SRE codes included in the coding framework is summarised in Table 1. 
 
3.2 Validation 
Table 2 shows how frequently the SRE-related diagnosis codes were paired with a bone 
metastasis code (C795), according to prostate cancer stage at diagnosis. These frequencies 
were high for patients with metastatic disease (all above 80%). They were lower for patients 
with localised or locally advanced disease, especially for the diagnosis codes with less 
specific definitions, including ‘collapsed vertebra, not elsewhere classified’ (M485), 
‘unspecified disease of spinal cord’ (C958), ‘other specified disease of spinal cord’ (C959), 
and ‘myelopathy in diseases classified elsewhere’ (C992). 
 
The surgical procedure codes were also frequently paired with a code for bone metastasis in 
men with metastatic disease at diagnosis (on average 75.4%). This frequency was again 
considerably lower in men with localised or locally advanced disease, which can be 
explained by the broad definitions of the included procedure codes for bone surgery. 
 
The linked RTDS records indicating radiotherapy for metastasis were paired with a bone 
metastasis code in 78.4% of men with metastatic disease at diagnosis. Lower frequencies 
were again observed in men with localised or locally advanced disease. 
 
These results demonstrate that a sensitive coding definition of SREs (SRE codes used 
without the requirement for pairing with a bone metastasis code) can lead to a substantial 
overestimation of the occurrence of skeletal events, especially in men diagnosed with 
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localised or locally advanced disease. For example, we found that the 5-year cumulative 
incidence of SREs for men diagnosed with metastatic disease was very similar, irrespective 
of whether the sensitive definition (44.3%) or the specific definition (42.2%) was used (Table 
3 and Figure 2). However, the difference in the cumulative incidence of SREs according to 
whether a sensitive or specific definition was used was much larger for men with localised 
disease (0.9% and 0.8%, respectively) and locally advanced disease (14.9% and 6.0%, 
respectively). 
 
3.3 Further exploration of the diagnosis and procedure codes related to SRE 
According to the specific coding definition of SREs, where SRE codes required pairing with a 
bone metastasis code, the majority of men who experienced a pathological fracture, spinal 
cord compression or both had some form of surgical and/or radiation-based intervention 
(77.1%, 86.0% and 93.7%, respectively; Table 4). In men diagnosed with metastatic prostate 
cancer, the most common SRE was radiotherapy for bone metastases with a 5-year 
cumulative incidence of 38.4%. The corresponding figures for pathological fractures, spinal 





A coding framework was developed to identify non-osteoporotic SREs in men diagnosed 
with prostate cancer based on diagnosis codes (for pathological fractures and spinal cord 
compression) and procedure codes (for bone surgery) in administrative hospital data, and 
palliative radiotherapy codes in a routinely collected radiotherapy dataset. 
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We demonstrated that a specific coding definition for a SRE (requiring a paired diagnosis 
code for bone metastasis) produced a very similar 5-year cumulative SRE incidence in men 
with metastatic disease, at the time of their prostate cancer diagnosis, as a sensitive coding 
definition (not requiring a paired diagnosis code for bone metastasis). However, the 5-year 
cumulative incidences were much lower for patients with localised or locally advanced 
disease at diagnosis when the specific coding definition was used as opposed to the 
sensitive coding definition. These results suggest that the true-positive detection rates of 
SREs with specific and sensitive coding definitions are almost the same but that the false-
positive detection rate with the specific coding definition is much lower than that of the 
sensitive coding definition. 
 
4.2 Comparison with other studies 
Comparing the incidence of SREs observed with our coding framework against results of 
other studies is the third step of the validation process. Our study is the largest study to 
report on the incidence of SREs in prostate cancer and is the first to do so in the UK using 
national population-based data for almost 80,000 patients with prostate cancer. We found 
that 39% of men with metastatic prostate cancer at the time of diagnosis experienced at 
least one SRE within 5 years. Six observational studies have used large administrative 
datasets to report on SREs in metastatic prostate cancer (2-7). Five of these studies have 
been conducted in the US (2-4, 6, 7) and four of these five used linked SEER-Medicare data 
(2-4, 6). The most recent of these studies was published in 2016 and used ICD-9 diagnosis 
codes and Healthcare Common Procedure Coding System (HCPCS) procedure codes to 
identify SREs in 3297 men diagnosed with metastatic disease between 2004 and 2009 (2). 
The coding framework used in this study compared well to the one used in ours but the 
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authors could not specify the target of radiotherapy. 40% of the men in this study 
experienced at least one SRE during a median follow-up of 19 months. 
 
Similar results, also based on linked SEER-Medicare data, were shown for a cohort of 4404 
men diagnosed with metastatic prostate cancer between 2005 and 2009 (44% experienced 
SREs after a median follow-up of 16.6 months) (3) and for a similar cohort of 9746 men 
diagnosed between 1999 and 2005, 44% experienced SREs after a median follow-up of 26 
months) (4). 
 
The fourth study that used SEER-Medicare data explored the impact of varying definitions of 
SREs in 8997 patients diagnosed between 2000 and 2009 (6). This study demonstrated that 
the observed SRE incidence depended on the codes included in the coding framework 
(specific versus sensitive codes), with codes used to identify pathological fractures being the 
most affected by differing definitions of a SRE. SRE incidence ranged from 46% (‘base case’ 
SRE definition) to 43% (‘alternative’ SRE definition) after a median follow-up of 18 months. 
The base case and alternative definitions differed with respect to the use of combinations of 
more sensitive and more specific definitions for the various SRE-related diagnoses and 
procedures. 
 
The fifth US study included 3919 men diagnosed with bone metastases between 2002 and 
2011 and recorded in the Thomson MedStat MarketScan Commercial Claims and 
Encounters database. A higher SRE rate was reported at 53% after a median follow-up of 




Finally, a Danish study analysed 3261 men diagnosed with bone metastases between 1999 
and 2007 and reported similarly high SRE rates (cumulative incidence of 46.1% at 1 year and 
53.8% at 5 years) (5). 
 
We found a lower incidence of SREs than the six studies described above. An important 
explanation for this difference is that significant transitions have been made in the 
management of metastatic disease and that all patients included in our study were 
diagnosed in 2010 or later. New chemotherapeutic options have been shown to reduce the 
incidence of SREs and were not being used at the time of these older studies (18-22). 
 
4.3 Methodological considerations 
A major limitation of our work – and of all other studies in this area – is that we were reliant 
on the accuracy of the clinical coding in the routinely collected hospital data. However, the 
accuracy of these data has been shown to be high when compared to clinical notes and is 
sufficiently robust to support its use in research (23). 
 
Incomplete information on cancer stage at the time of diagnosis is a further limitation 
because men with missing stage were excluded. We have previously shown that stage data 
is more often missing in prostate cancer patients older than 80 years and in those from a 
more socioeconomically deprived background (24). However, it is unlikely that this selective 
inclusion will have had a major impact on our results (comparing SRE incidence according to 
cancer stage at diagnosis), because there is no obvious plausible mechanism that would 
explain why cancer stage at diagnosis would have a different impact on the occurrence of 
SREs according to whether or not this information had been recorded. 
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Lastly, the use of administrative hospital data ensures that only severe events that require 
hospital events are captured. In this way, asymptomatic vertebral fractures are not 
identified with our coding framework which limits any potential over-estimation of the SRE 
incidence. 
 
A key strength of our study is that the administrative hospital data and the routinely 
collected radiotherapy data are likely to have identified the majority of the relevant hospital 
and radiotherapy episodes. This is because more than 95% of patients diagnosed with 
prostate cancer in England are treated in the NHS, making it a nationally representative 
patient cohort. Furthermore, it is extremely rare that patients who have had their initial 
treatment in the English NHS will switch to a private healthcare provider later in their 
treatment pathway and this minimises underestimation of the SRE incidence due to loss to 
follow-up (28).  
 
A unique feature of our study is that we compared the cumulative incidence of SREs 
according to prostate cancer stage at the time of diagnosis. This comparison allowed us to 
compare the performance of specific and sensitive coding definitions allowing for an 
assessment of coding consistency. The preference to use the specific coding definition of 
SREs, where SRE codes require pairing with a bone metastasis code, prevents substantial 
misclassification and overestimation of SREs and adds to the reliability of the coding 
framework.  
 
Lastly, by using backward coding we created greater certainty that our coding framework 
also included diagnosis and procedure codes that are difficult to determine a priori. Two 
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frequently occurring diagnosis codes were added to our coding framework which will have 
further reduced the extent to which our approach underestimates the SRE incidence.  
 
4.4 Implications 
It is the first time that an administrative hospital database using ICD-10 diagnosis codes has 
been used to detect patients with a SRE. Given our explicit and transparent coding 
framework, our results are reproducible and applicable to other national administrative 
databases that use the same diagnosis codes and related procedure codes. Equally a similar 
coding framework could be applied to other cancer groups. Based on these results, we 
recommend that the specific coding definition for a SRE (requiring a paired diagnosis code 
for bone metastasis) is used in large-scale studies of routinely collected data to identify 
disease progression and compare treatment outcomes in prostate cancer. 
 
In many countries, cancer registries are highly accurate and complete in identifying patients 
diagnosed with cancer, but their performance is considerably poorer in identifying disease 
progression. We have shown, along with studies from outside the UK, that administrative 
hospital data can be used to this end. The coding framework outlined in this paper can be 
used to detect SREs as a key outcome for comparisons of prostate cancer treatments. 
Capturing events other than death is important in order to measure highly relevant clinical 
outcomes which happen earlier so that a shorter follow-up is required for studies of 
therapeutic outcomes in prostate cancer patients.  
 
The treatment options for metastatic prostate cancer are rapidly developing and now 
chemotherapy, in the neoadjuvant and castrate-resistant settings, is able to reduce the 
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incidence of SREs and prolong survival (30). The ability to identify the occurrence of SREs in 
a ‘real-world’ national population is paramount in order to describe disease trends and 
assess the impact of novel treatments and their value (31). 
 
5. CONCLUSIONS: 
Combinations of diagnosis and procedure codes in administrative hospital data linked to a 
national radiotherapy dataset can be used to identify non-osteoporotic SREs across cancer 
stages. Identifying SREs based on these codes provides an accurate measure of cancer 
progression which can be used for comparing treatment outcomes in routinely collected 
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Men diagnosed with prostate cancer (2010-2013) 
152,851 
Complete Case Analysis 
79,265 










Cumulative incidence of the first occurrence of a skeletal-related event in men with 




























ICD-10 diagnosis code and OPCS-4 procedure code definitions for skeletal-related events. 
 
 Code Definition 
ICD-10 diagnosis codes  
Pathological fracture   
M485 Collapsed vertebra, not elsewhere classified 
M495 Collapsed vertebra in diseases classified elsewhere 
M844 Pathological fracture, not elsewhere classified 
M907* Fracture of bone in neoplastic disease 
Spinal cord compression   
G550 Nerve root and plexus compressions in neoplastic disease 
G834 Cauda equine syndrome 
G952 Other and unspecified spinal cord compression 
G958 Unspecified disease of spinal cord 
G959 Other specified disease of spinal cord 
G992* Myelopathy in diseases classified elsewhere 
OPCS-4 procedure codes  
Spinal surgery  
V22-7, V67-8 Decompression operations on spine 
V28 Insertion of lumbar interspinous process spacer 
V38-4 Fusion of joint/stabilisation of spine 
V41 Instrumental correction of deformity of spine 
V43, V47 Extirpation of lesion/biopsy of spine 
V44-6, Decompression/reduction/fixation of fracture of spine 
V55 Levels of spine 
Bone surgery  
W05 Prosthetic replacement of bone 
W08-9 Excision of bone/extirpation of lesion of bone 
W16 Division of bone 
W19-26 Reduction of fracture 
W28, W30 Internal/external fixation of bone 
W37-41, W93-5 Replacement of hip/knee joint 
W46-8 Prosthetic replacement of head of femur 
W65-7 Reduction of traumatic dislocation of joint 









Frequency of the first occurrence of codes for skeletal-related events with and without a diagnosis code for bone metastasis, stratified 
by prostate cancer stage at diagnosis. 




First occurrence of a SRE* code per man 
 
Metastatic Locally advanced Localised 
   
SRE paired with 
bone metastasis 
n (%) 
SRE not paired with 
bone metastasis 
n (%) 
SRE paired with bone 
metastasis 
n (%) 
SRE not paired with 
bone metastasis 
n (%) 
SRE paired with 
bone metastasis 
n (%) 
SRE not paired with 
bone metastasis 
n (%) 
DIAGNOSIS CODES       
Pathological fracture codes       
Any code (n=1313) 918 (95.8) 40 (4.2) 146 (62.4) 88 (37.6) 51 (42.2) 70 (57.9) 
M485 (n=206) 62 (80.5) 15 (19.5) 13 (17.8) 60 (82.2) 7 (12.5) 49 (87.5) 
M495 (n=294) 233 (99.6) 1 (0.4) 32 (88.9) 4 (11.1) 21 (87.5) 3 (12.5) 
M844 (n=127) 57 (82.6) 12 (17.4) 9 (29.0) 22 (71.0) 7 (25.9) 20 (74.1) 
M907 (n=794) 635 (97.2) 18 (2.8) 101 (91.8) 9 (8.2) 26 (83.9) 5 (16.1) 
Spinal cord compression codes       
Any code (n=1848) 1409 (97.4) 37 (2.6) 181 (69.6) 79 (30.4) 55 (38.7) 87 (61.3) 
G550 (n=441) 378 (99.0) 4 (1.1) 45 (97.7) 2 (4.3) 12 (100) 0 (0) 
G834 (n=207) 161 (98.2) 3 (1.8) 26 (84.9) 5 (16.1) 5 (41.7) 7 (58.3) 
G952 (n=661) 505 (93.5) 35 (6.5) 62 (74.8) 22 (26.2) 20 (54.1) 17 (46.0) 
G958 (n=32) 11 (84.6) 2 (15.4) 3 (16.7) 15 (83.3) 1 (9.1) 10 (90.9) 
G959 (n=50) 21 (87.5) 3 (12.5) 3 (42.9) 42 (31.1) 0 (0) 8 (100) 
G992 (n=983) 748 (97.7) 18 (2.4) 93 (68.9) 4 (4.1) 28 (34.2) 54 (65.9) 
PROCEDURE CODES       
Surgery codes       
OPCS-4 V/W codes (n=5186)** 872 (75.4) 284 (24.6) 128 (7.4) 1603 (92.6) 43 (1.9) 2256 (98.1) 
RTDS palliative radiotherapy codes***       
RT episodes with valid HES record**** 
(n=5115) 3795 (89.7) 438 (10.4) 585 (77.1) 174 (22.9) 89(72.4) 34 (27.6) 




Cumulative incidence of skeletal-related events according to prostate cancer stage at 
diagnosis for men with prostate cancer. 
 




incidence (%) 95% CI   
 
Specific definition   
Localised  0.8 1.0 - 1.1 
Locally advanced 6.0 5.5 - 6.4 
Metastatic 42.2 41.2 - 43.3 
 
Sensitive definition     
Localised 0.9 8.6 - 9.4 
Locally advanced 14.9 14.3 - 15.6 







Frequency that patients with pathological fractures and/or spinal cord compression, 








skeletal event  
Bone surgery 
n (%)  
Radiotherapy 
n (%)  
Both 
n (%)  
Neither 




Pathological fracture 120 247 189 198 754 
 (15.9) (32.8) (25.1) (26.3) (100) 
Spinal cord compression 37 924 131 192 1284 
 (2.9) (72.0) (10.2) (15.0) (100) 
Both 26 195 119 21 361 
 (7.2) (54.0) (33.0) (5.8) (100) 
Neither 225 3888 196 72,557 76,866 
 (0.3) (5.1) (0.3) (94.4) (100) 
Total 408 5,254 635 72,968 79,265 
 (0.5) (6.6) (0.8) (92.1) (100) 
 
